跳转至内容
Merck
所有图片(1)

主要文件

SCP0110

Sigma-Aldrich

组织蛋白酶抑制剂

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C35H59N11O5
分子量:
713.91
UNSPSC代码:
12352200
NACRES:
NA.32

方案

≥95% (HPLC)

表单

lyophilized

组成

Peptide Content, ≥55%

储存条件

protect from light

储存温度

−20°C

Amino Acid Sequence

Arg-Lys-Leu-Leu-Trp-NH2

一般描述

组织蛋白酶L抑制剂是一种组蛋白H3加工酶。它在维持表皮稳态、毛囊正常形态发生和周期中起重要作用。组织蛋白酶L参与蛋白降解。它可能会调节免疫系统的正常功能。组织蛋白酶L可调节巨噬细胞死亡、坏死核心形成和动脉粥样硬化斑块不稳定进展。

应用

组织蛋白酶L是一种可代谢胶原蛋白和弹性蛋白的溶酶体半胱氨酸蛋白酶。组织蛋白酶L的作用和活性可借助肽抑制剂如五肽酰胺RKLLW-NH2(Arg-Lys-Leu-Leu-Trp-NH2)而得以研究。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Protease signalling: the cutting edge
Turk B, et al.
The Embo Journal, 31(7), 1630-1643 (2012)
Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells
Liu J, et al.
Atherosclerosis, 184(2), 302-311 (2006)
Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis
Li W, et al.
Atherosclerosis, 202(1), 92-102 (2009)
A Brinker et al.
European journal of biochemistry, 267(16), 5085-5092 (2000-08-10)
By screening a combinatorial pentapeptide amide collection in an inhibition assay, we systematically evaluated the potential of 19 proteinogenic amino acids and seven nonproteinogenic amino acids to serve as building blocks for inhibitors of human cathepsin L. Particularly efficient were
V Turk et al.
The EMBO journal, 20(17), 4629-4633 (2001-09-05)
From their discovery in the first half of the 20th century, lysosomal cysteine proteases have come a long way: from being the enzymes non-selectively degrading proteins in lysosomes to being those responsible for a number of important cellular processes. Some

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持